Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK369796 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Anti-malarial experimental drug | EXPERIMENTAL | After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules. |
| Matching placebo | ACTIVE_COMPARATOR | After randomization subjects will receive matching placebo of GSK3697969. |
| Name | Type | Description |
|---|---|---|
| GSK369796 | DRUG | Anti-malarial |
| Placebo | DRUG | Placebo matching GSK369796 |
Inclusion Criteria: * Healthy adults between the ages of 18 to 40, inclusive. * Female subjects must be of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or bilateral oophrectomy or postmenopausal defined as 6 months of spontan...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
GSK369796 is an investigational small molecule being developed for the treatment of malaria. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its safety and tolerability.
The specific molecular target of GSK369796 has not been disclosed. The drug is being developed as a small molecule for malaria, but its mechanism of action is not publicly detailed in the available clinical trial information.
GSK369796 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy subjects.
GSK369796 is in Phase 1 clinical development. A single Phase 1 trial has been completed, involving 41 healthy volunteers in the United Kingdom. The drug remains investigational and has not yet received regulatory approval for any indication.
GSK369796 has one completed clinical trial registered as NCT00675064, a single-blind, placebo-controlled, randomized study testing single ascending doses in healthy subjects. The trial enrolled 41 participants in the United Kingdom and was completed, with no active trials currently ongoing.
No alternative names for GSK369796 have been disclosed. The drug is identified solely by its development code GSK369796 in clinical trial registrations and scientific literature. It is not known to be marketed under any other brand name.